ARID1A mutations have been found enriched in MSI-H neoplasms including endometrial carcinomas [47–49], ovarian carcinomas [50], gastric adenocarcinomas [51, 52], colon cancers [53, 54], and prostate cancers [53]. Here, ARID1A is linked to ovarian carcinoma.